<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00815594</url>
  </required_header>
  <id_info>
    <org_study_id>2008TR-LX-001</org_study_id>
    <nct_id>NCT00815594</nct_id>
  </id_info>
  <brief_title>Bleb Vascularity Change After Subconjunctival Injection Bevacizumab</brief_title>
  <official_title>Bleb Vascularity Change After Subconjunctival Injection of Bevacizumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Capital Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Capital Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The occurrence of conjunctival scarring finally leads to the obstruction of the fistula tract
      created by the filtering surgery. Vascular endothelial growth factor is thought to be a key
      role in the formation of conjunctival scar, which play a pivotal role in the wound-healing
      process. So it seems that the recombinant human anti-VEGF antibody could inhibit
      angiogenesis, and reduce the conjunctival vascular formation in the wound-healing process
      after glaucoma filtering surgery.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>December 2008</start_date>
  <completion_date type="Anticipated">May 2009</completion_date>
  <primary_completion_date type="Anticipated">March 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>bleb vascular change</measure>
    <time_frame>one day, one week, one month</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Bleb Vascularity</condition>
  <condition>Conjunctival Scarring</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>0.05ml, 1.25mg</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Glaucoma patients after trabeculectomy whose bleb is hyperaemia

        Exclusion Criteria:

          -  Affected eye has normal IOP

          -  Not allergic with Avastin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liu Xuan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>An ophthalmologist in Tongren hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tongren hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 29, 2008</study_first_submitted>
  <study_first_submitted_qc>December 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2008</study_first_posted>
  <last_update_submitted>December 29, 2008</last_update_submitted>
  <last_update_submitted_qc>December 29, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2008</last_update_posted>
  <responsible_party>
    <name_title>Wang NingLi</name_title>
    <organization>Beiing Tongren hospital</organization>
  </responsible_party>
  <keyword>bleb</keyword>
  <keyword>vascular change</keyword>
  <keyword>bevacizumab</keyword>
  <keyword>trabeculectomy</keyword>
  <keyword>Bleb vascularity associated with increased scarring activity</keyword>
  <keyword>Conjunctival scarring finally leads to the obstruction of the fistula tract created by the filtering surgery</keyword>
  <keyword>the recombinant human anti-VEGF antibody could inhibit angiogenesis of conjunctiva.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cicatrix</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

